Technical Analysis for DMTK - DermTech, Inc.

Grade Last Price % Change Price Change
F 0.66 -4.14% -0.03
DMTK closed down 4.14 percent on Monday, March 18, 2024, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup -4.14%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.14%
Spinning Top Other -4.14%
Narrow Range Bar Range Contraction -4.14%
Inside Day Range Contraction -4.14%
Wide Bands Range Expansion -4.14%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 20 hours ago
Down 3% about 20 hours ago
Down 2 % about 20 hours ago
Down 1% about 20 hours ago
10 DMA Resistance about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

DermTech, Inc. Description

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.


Classification

Sector: Industrials
Industry: Conglomerates
Keywords: Medicine Cancer Melanoma Dermatology Gene Expression Diagnostic Tests Risk Assessment Pathology Biopsy Skin Cancer Assessment Products Melanoma Skin Cancer Pigmented Lesion Cutaneous Conditions Non Melanoma Skin Cancer

Is DMTK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.66
52 Week Low 0.63
Average Volume 373,419
200-Day Moving Average 1.84
50-Day Moving Average 1.17
20-Day Moving Average 0.96
10-Day Moving Average 0.71
Average True Range 0.10
RSI (14) 25.93
ADX 33.95
+DI 11.71
-DI 30.13
Chandelier Exit (Long, 3 ATRs) 1.11
Chandelier Exit (Short, 3 ATRs) 0.92
Upper Bollinger Bands 1.53
Lower Bollinger Band 0.39
Percent B (%b) 0.24
BandWidth 118.87
MACD Line -0.17
MACD Signal Line -0.15
MACD Histogram -0.0208
Fundamentals Value
Market Cap 22.68 Million
Num Shares 34.2 Million
EPS -3.48
Price-to-Earnings (P/E) Ratio -0.19
Price-to-Sales 2.98
Price-to-Book 0.57
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.74
Resistance 3 (R3) 0.74 0.73 0.72
Resistance 2 (R2) 0.73 0.71 0.72 0.72
Resistance 1 (R1) 0.69 0.70 0.69 0.69 0.72
Pivot Point 0.68 0.68 0.67 0.67 0.68
Support 1 (S1) 0.65 0.66 0.64 0.64 0.61
Support 2 (S2) 0.63 0.65 0.63 0.61
Support 3 (S3) 0.60 0.63 0.60
Support 4 (S4) 0.59